R. Cortès

ORCID: 0000-0003-4559-3447
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • X-ray Diffraction in Crystallography
  • Crystallization and Solubility Studies
  • Magnetism in coordination complexes
  • Metal complexes synthesis and properties
  • Crystallography and molecular interactions
  • Ferrocene Chemistry and Applications
  • Cancer, Hypoxia, and Metabolism
  • Metal-Organic Frameworks: Synthesis and Applications
  • Lanthanide and Transition Metal Complexes
  • Organometallic Complex Synthesis and Catalysis
  • Crystal structures of chemical compounds
  • Acute Myeloid Leukemia Research
  • Natural product bioactivities and synthesis
  • Advanced Condensed Matter Physics
  • Histone Deacetylase Inhibitors Research
  • Epigenetics and DNA Methylation
  • Cancer, Lipids, and Metabolism
  • Metabolomics and Mass Spectrometry Studies
  • Crystal Structures and Properties
  • Synthesis and Biological Evaluation
  • Organic and Molecular Conductors Research
  • Natural Compounds in Disease Treatment
  • Molecular Junctions and Nanostructures
  • Physics of Superconductivity and Magnetism
  • Cancer Mechanisms and Therapy

Clínica Diagonal
2013-2022

Universitat de Barcelona
2011-2021

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2018-2021

Instituto de Salud Carlos III
2018-2021

Consejo Superior de Investigaciones Científicas
2013-2018

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2011-2018

Instituto de Acuicultura Torre de la Sal
2013

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2011

Universidade Federal de Alfenas
2011

Institute of Inorganic Chemistry of the Slovak Academy of Sciences
2011

Abstract Acute myeloid leukemia remains difficult to treat due strong genetic heterogeneity between and within individual patients. Here, we show that Pyruvate dehydrogenase kinase 1 (PDK1) acts as a targetable determinant of different metabolic states in acute (AML). PDK1 low AMLs are OXPHOS-driven, enriched for leukemic granulocyte-monocyte progenitor (L-GMP) signatures, associated with FLT3 -ITD NPM1 cyt mutations. high however OXPHOS , wild type stemness signatures. Metabolic can even...

10.1038/s41467-022-28737-3 article EN cc-by Nature Communications 2022-03-01

Cisplatin is a platinum-based compound that acts as an alkylating agent and used to treat variety of malignant tumors including lung cancer. As cisplatin has significant limitations in the clinic, alternative platinum compounds such cycloplatinated complexes have been considered attractive anti-tumor agents. Here, we report antiproliferative activity novel diastereomerically pure complex (Sp,1S,2R)-[Pt{(κ2-C,N)[(η5-C5H3)–CH˭N–CH(Me)–CH(OH)–C6H5]Fe(η5-C5H5)}Cl(DMSO)] 6a, against A549...

10.1039/c3mt00194f article EN Metallomics 2014-01-01

KRAS mutations in non-small cell lung cancer (NSCLC) are a predictor of resistance to EGFR-targeted therapies. Because approaches target RAS signaling have been unsuccessful, targeting metabolism might help develop new strategy that could overcome drug such cancer. In this study, we applied large screening quantitative proteomic analysis evidence key enzymes involved metabolic adaptations We carried out the two KRAS-mutated NSCLC lines (A549 and NCI-H460) non tumoral bronchial line (BEAS-2B)...

10.1021/pr500327v article EN Journal of Proteome Research 2014-07-16

The pentose phosphate pathway (PPP) plays an essential role in the metabolism of breast cancer cells for management oxidative stress and synthesis nucleotides. 6-phosphogluconate dehydrogenase (6PGD) is one key enzymes branch PPP involved nucleotide biosynthesis redox maintenance status. Here, we aimed to analyze functional importance 6PGD a cell model. Inhibition MCF7 reduced proliferation showed significant decrease glucose consumption increase glutamine consumption, resulting important...

10.3390/biology10020085 article EN cc-by Biology 2021-01-23

The new compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) was prepared and fully characterized. reactions of A with ligands ArCH═NCH2CH2NMe2 (Ar = 2-BrC6H4, 1a; 2,6-Cl2C6H3, 1b; 4-ClC6H4, 1c; 2-Cl,6-FC6H3, 1d) were studied under different conditions produced platinum(II) compounds [Pt(4-FC6H4)2(ArCH═NCH2CH2NMe2)] (2b–2d), containing a bidentate [N,N′] ligand, as well cyclometalated platinum(IV) or such [PtBr(4-FC6H4)2(C6H4CH═NCH2CH2NMe2)] (4a) [PtCl{(3-FC6H3)(2-XC6H3)CH═NCH2CH2NMe2}] (5b: X Cl; 5d: F),...

10.1021/om5000908 article EN Organometallics 2014-03-18

ADVERTISEMENT RETURN TO ISSUEPREVArticleSynthesis and Crystal Structure of MCu(edta).cntdot.4H2O: Molecular Precursors for MCuO2 (M = Ca, Sr, Ba)M. Insausti, J. L. Pizarro, Lezama, R. Cortes, E. H. Bocanegra, M. I. Arriortua, T. RojoCite this: Chem. Mater. 1994, 6, 5, 707–713Publication Date (Print):May 1, 1994Publication History Published online1 May 2002Published inissue 1 1994https://pubs.acs.org/doi/10.1021/cm00041a023https://doi.org/10.1021/cm00041a023research-articleACS...

10.1021/cm00041a023 article EN Chemistry of Materials 1994-05-01

Breath analysis holds the promise of a non-invasive technique for diagnosis diverse respiratory conditions including chronic obstructive pulmonary disease (COPD) and lung cancer. contains small metabolites that may be putative biomarkers these conditions. However, discovery reliable is considerable challenge in presence both clinical instrumental confounding factors. Among latter, time drifts are highly relevant, as since question short long-term validity predictive models. In this work we...

10.1088/1752-7163/aaa492 article EN cc-by Journal of Breath Research 2018-01-02
Coming Soon ...